Metformin hydrochloride 500 mg. Purchase is Two Blister 2 x 10 tablets = 20 Tablets.
Metformin, marketed under the tradename Glucophage among others, is the first-line medication for the treatment of type 2 diabetes. It is also used in the treatment of polycystic ovary syndrome. Limited evidence suggests metformin may prevent the cardiovascular disease and cancer complications of diabetes. It is not associated with weight gain. It is taken by mouth.
Metformin is generally well tolerated. Common side effects include diarrhea, nausea, and abdominal pain. It has a low risk of developing low blood sugar. High blood lactic acid levels is a concern if prescribed inappropriately and in overdose. It should not be used in those with liver disease or kidney problems. While there is no clear harm if used during pregnancy, insulin is generally preferred for gestational diabetes. Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues.
Metformin was discovered in 1922. Study in humans began in 1950s by French physician Jean Sterne. It was introduced in France in 1957 and the United States in 1995. It is on the World Health Organization’s List of Essential Medicines, the most important medications needed in a basic health system. Metformin is believed to be the most widely used medication for diabetes which is taken by mouth. It is available as a generic medication.The wholesale price is between 0.21 and 5.55 USD per month as of 2014. In the United States it costs between 5 and 25 USD per month.
Metformin is primarily used for type 2 diabetes, but is increasingly being used in polycystic ovary syndrome
The UK Prospective Diabetes Study, a large clinical trial performed in 1980-90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents. However, accumulated evidence from other and more recent trials has reduced confidence in the efficacy of metformin for cardiovascular disease prevention. Treatment guidelines for major professional associations including the European Association for the Study of Diabetes, the European Society for Cardiology, and the American Diabetes Association, now describe evidence for the cardiovascular benefits of metformin as equivocal. According to the American College of Physicians in 2012, low-quality evidence indicates metformin monotherapy is associated with lower cardiovascular mortality than sulfonylurea monotherapy and metformin monotherapy is associated with fewer cardiovascular events than metformin-sulfonylurea combination therapy. Evidence for other comparisons is described as unclear. A 2014 review found tentative evidence that people treated with sulfonylureas have fewer non-fatal cardiovascular events than those treated with metformin (RR 0.67) but a higher risk of severe low blood sugar events (RR 5.64). There was not enough data available to determine the relative risk of death or of death from heart disease.
Metformin has little or no effect on body weight compared with placebo in type 2 diabetes, although it causes weight loss compared with sulfonylureas, since sulfonylureas are associated with weight gain.
There is some limited evidence that metformin may be associated with weight loss in obesity in the absence of diabetes. Metformin has a lower risk of hypoglycemia than the sulfonylureas, although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose. Metformin modestly reduces LDL and triglyceride levels.
One blisters contain 10 tablets, each tablets contain Metformin 500mg.